Article

Drug Cost Control in Oncology

Panel members are asked to discuss what drives the cost of drugs in cancer care. They also discuss the role companion diagnostics and personalized medicine play in oncology.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Sundar Jagannath
Senator Vincent Polistina (R, New Jersey)
Senator Vincent Polistina (R, New Jersey)
Jeffrey Fitzgerald, JD
CK Wang, MD, COTA
Eric Lander, MD
Related Content
As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor
Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.
The Center for Biosimilars podcast banner
July 29th 2025

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Skylar Jeremias Hillel P. Cohen, PhD Giuseppe Randazzo
Doctor with patient | Image credit: Chinnapong - stock.adobe.com
July 25th 2025

5 Major Changes the Trump Administration Has Made in Health Care

Julia Bonavitacola
At the 6-month anniversary of the inauguration in January, The American Journal of Managed Care® looks back at the changes made by the Trump administration that could have lasting effects in health care.
Managed Care Cast
Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey
Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization
The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com
July 24th 2025

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

Chris Ryan
The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval
Flu vaccine | Image credit: Leigh Prather - stock.adobe.com
July 24th 2025

Federal Recommendations for Vaccines Containing Thimerosal Rescinded

Julia Bonavitacola
Thimerosal, a mercury-based preservative, has been incorrectly linked to the development of autism by antivaccine groups.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo